Sarah Donahue, NP

Cindi received her BSN at Valparaiso University in Indiana, her MSN at University of North Carolina Chapel Hill and her Nurse Practitioner certificate from Texas Women’s University.
Cindi has a varied background in oncology nursing including the role of a clinical nurse specialist at Duke University Medical Center, development and management of a multi-disciplinary breast cancer center at John Muir Medical Center in Walnut Creek, California, a clinical trials nurse with US Oncology in Dallas and a nurse practitioner at the Mary Crowley Medical Research Center at Medical City of Dallas. She is currently working part time as a nurse practitioner with Texas Oncology in Plano, Texas.
Cindi has presented many times on topics ranging from breast cancer to symptom management and new drug development, written articles and textbook chapters and precepted students in graduate nursing programs. She currently volunteers and helps manage the clinical team for GDAS Cancer Clinic a 100% volunteer clinic that provides chemotherapy and follow up for individuals with potentially curative cancers in need of adjuvant chemotherapy. Her three passions currently are breast cancer, sexuality and genetic counseling for individuals with a wide range of cancers.

Tiffany Richards, PhD, ANP-BC, is an Advanced Practice Nurse at the University of Texas MD Anderson Cancer Center. She specializes in the treatment of patients with multiple myeloma, and her research focuses on the development of targeted therapies for patients with this disease. Dr. Richards serves as Co-Facilitator of the Multiple Myeloma Support Group and is an active member of the International Myeloma Foundation Nurse Leadership Board and the Oncology Nursing Society. She has authored or coauthored numerous peer-reviewed publications and book chapters focusing on novel therapeutics and treatment strategies to optimize the care of patients with multiple myeloma.

Download Presentation

Download Objectives

Download Resume

Copyright 2021  GLAONS   All rights reserved.

Katy Wong, PhD

Dr. Nakhoda is an assistant professor in the Department of
Hematology/Oncology at Fox Chase Cancer Center. She specializes in B-cell lymphomas and leukemias. She has particular interest in improving toxicities associated with cancer therapeutics in lymphoma. She completed her internal medicine residency at University of Maryland and her Hematology/Oncology fellowship at Fox Chase Cancer Center.





Ms. Rogers is a Nurse Practitioner at Fox Chase Cancer Center in Philadelphia, Pennsylvania. She obtained her BSN from
Trenton State College, her MN from UCLA and her post-master’s NP certificate from Temple University. Ms. Rogers has over
40 years of oncology experience with most of that time focused on the care of patients with hematologic malignancies. She has
authored many peer-reviewed journal articles and book chapters, as well as given many presentations related to the care of patients with
hematologic malignancies and symptom management. Ms. Rogers has held leadership positions in multiple organizations such as serving on the
ONS Board of Directors, Chair of the ONS Nominating Committee, and Chair of the Advanced Practice Test Development Committee of the
Oncology Nursing Certification Corporation. Currently, she is a member of the Education Committee of the Advanced Practitioner Society for
Hematology and Oncology (APSHO).

Shazia K. Nakhoda, MD & Barbara Rogers CRNP

Rhonda Hewitt, NP

Tiffany Richards, PhD

Cindi Bedell MSN, RN, ANP-C

​Nurse Practitioner, Texas Oncology

Download Presentation

Download Objectives

Sarah Donahue, MPH, NP, AOCNP®, is a nurse practitioner at the Carol Franc Buck Breast Cancer Center of the Helen Diller Family Comprehensive Cancer
Center at the University of California San Francisco.
She specializes in the treatment of patients with early stage and metastatic breast cancer being treated with chemotherapy, hormone therapy, or targeted therapy.
Ms. Donahue has authored or coauthored numerous publications focused on the treatment and management of patients with breast cancer.

Karen L. Reckamp, MD

Katy is a Senior Medical Science Liaison with Foundation Medicine where she works with healthcare professionals on the West Coast to better understand their genomic testing needs. Katy holds a Ph.D. form the University of Illinois College of Medicine in Pharmacology and a B.S in biochemistry from Cal Poly. She did her post-doctoral work at Tufts Medical Center focusing on circulating biomarkers and lung cancer. Katy has been working in medical affairs for 7 years and joined Foundation Medicine in 2019. 

PRESENTERS

Click on each link below for a printable file.

Lidia P. Lopez, NP


Download Objectives​


Download Presentation

Download Objectives

Ms. Rhonda Hewitt is a Hematology Nurse Practitioner with Stanford Health Care in Palo Alto, California. She also is the Hematology APP Fellow Clinical Lead at Stanford Health Care, a Clinical Assistant Professor of Nursing at the University of California San Francisco Nursing School, and serves on the membership committee for the APSHO. She earned her Bachelor of Science in Nursing from the University of British Columbia and her Master of Science Nursing Acute Practitioner degree with a focus on Hematology/Oncology at the University of
Washington. Ms. Hewitt has almost 30 years of diverse experience in the field of
Hematology/Oncology/BMT and is a passionate educator. Rhonda has lectured locally, nationally, & internationally on topics such as multiple myeloma, acute & chronic leukemias, myeloproliferative neoplasms, and oncologic emergencies including tumor lysis syndrome, DIC, infusion reactions,  febrile  neutropenia/sepsis, hypercalcemia.

Teresa Knoop, RN


Teresa Knoop is an Assistant Director of the Clinical Trials Shared Resource at the Vanderbilt-Ingram Cancer Center in Nashville, TN. She graduated from Murray State University in Murray,KY with a BSN and earned her Master’s Degree in Nursing from the Vanderbilt University School of Nursing. Teresa is an Advanced Oncology Certified Nurse through the Oncology Nursing Society and is a Certified Clinical Research Professional through the Society of Clinical Research Associates. She has published articles in nursing journals and speaks frequently on the topics of molecularly targeted cancer therapies and cancer clinical trials.


Nazy Zomorodian, RNC, MSN, CUNP, CCRC, is a nurse practitioner in the Department of Urology at the University of California Los Angeles (UCLA) Medical Center, where she is also the Director of Genitourinary (GU) Clinical Trials. In addition, she is an Assistant Professor of Urology at the David Geffen School of Medicine at UCLA and is certified by the Association of Clinical Research Professionals as a Clinical Research Coordinator. Ms. Zomorodian specializes in the treatment of patients with genitourinary malignancies, including kidney, prostate, and bladder cancer, and her research focuses on developing novel therapeutics and improving outcomes for patients with these diseases.

Nazy Zomorodian,  RNC, MSN, CUNP, CCRC

Karen L. Reckamp, MD, MS is Clinical Professor in Medicine, Director of the Division of Medical Oncology at Cedars-Sinai Medical Center. She is also the Associate Director of Clinical Research for the Cedars Sinai Cancer, and Medical Oncology Director of the Women’s Guild Lung Institute at Cedars Sinai Medical Center.
She received a master’s degree in Clinical Investigation from the department of Biomathematics at UCLA. Dr. Reckamp also serves as the Associate Director of Clinical Research for the Samuel Oschin Comprehensive Cancer Institute (SOCCI). She obtained my medical degree at the University of Chicago, Pritzker School of Medicine in 1998 with AOA distinction, and trained in Internal Medicine at Washington University’s Barnes-Jewish Hospital. Dr. Reckamp completed fellowship training in Hematology/Oncology at the David Geffen School of Medicine, UCLA in June 2004, and completed a Master of Science degree in Clinical Research (MSCR).
Dr. Reckamp serves as a committee member for the Association of American Cancer Institute’s Physician Clinical Leadership Initiative. She leads many phase I, II and III studies funded by the NCI, internal funds and industry. Dr. Reckamp is a member of ASCO, AACR, International Association for the Study of Lung Cancer, and SWOG. She participated in the ASCO Leadership Development Program and led the Scientific Committee for metastatic lung cancer for the ASCO annual meeting. Dr. Reckamp has been the past recipient of many honors including American Lung Association, Lung Force Honoree in 2018. She has also authored or co-authored many manuscripts in the field of Thoracic Oncology in high impact journals, including the New England Journal of Medicine.